06:47:53 Europe / Stockholm

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2025-05-06 Annual General meeting
2025-02-12 Year-end Report 2024
2024-11-07 Quarterly Report 2024-Q3
2024-08-29 Quarterly Report 2024-Q2
2024-07-30 Split QLIFE 2000:1
2024-05-28 Quarterly Report 2024-Q1
2024-05-08 Ex-date Ordinary Dividend QLIFE 0.00 SEK
2024-05-07 Annual General meeting
2024-02-08 Year-end Report 2023
2024-01-16 Extra General Meeting 2023
2023-11-13 Quarterly Report 2023-Q3
2023-08-17 Quarterly Report 2023-Q2
2023-05-26 Quarterly Report 2023-Q1
2023-05-05 Ex-date Ordinary Dividend QLIFE 0.00 SEK
2023-05-04 Annual General meeting
2023-03-24 Extra General Meeting 2022
2023-02-16 Year-end Report 2022
2022-11-25 Quarterly Report 2022-Q3
2022-08-29 Quarterly Report 2022-Q2
2022-05-06 Ex-date Ordinary Dividend QLIFE 0.00 SEK
2022-05-05 Annual General meeting
2022-05-05 Quarterly Report 2022-Q1
2022-02-17 Year-end Report 2021
2021-11-08 Quarterly Report 2021-Q3
2021-08-16 Quarterly Report 2021-Q2
2021-05-06 Ex-date Ordinary Dividend QLIFE 0.00 SEK
2021-05-05 Annual General meeting
2021-05-05 Quarterly Report 2021-Q1
2021-02-18 Year-end Report 2020
2020-11-19 Extra General Meeting 2020
2020-11-18 Quarterly Report 2020-Q3
2020-08-18 Quarterly Report 2020-Q2
2020-05-22 Ex-date Ordinary Dividend QLIFE 0.00 SEK
2020-05-20 Annual General meeting
2020-05-20 Quarterly Report 2020-Q1

Description

CountrySweden
ListFirst North Stockholm
SectorHealth care
IndustryMedical technology
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2024-06-07 12:41:18

The exercise period for warrants series TO 4 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue") begins today, 7 June 2024.

Terms for warrants series TO 4 in brief:
  • The exercise price is SEK 0.02 per share.
  • The exercise period runs from 7 - 21 June 2024.
  • Each warrant entitles the holder to subscribe for one (1) share. Upon exercise of all 1,048,696,624 outstanding warrants, 1,048,696,624 shares will be issued.
  • If the warrants are fully exercised, the Company will receive approximately MSEK 21.0 before issue costs.
  • Upon full exercise of all warrants, the number of shares in Qlife will increase with 1,048,696,624 to 5,685,729,046 shares, and the share capital will increase with SEK 3,932,612.34 to SEK 21,321,483.9225.
  • The outcome is planned to be announced on June 25, 2024.

In total, Qlife issued 131,087,078 units in the Rights Issue, each unit consisting of twenty-three (23) shares, eight (8) warrants series TO 4 and eight (8) warrants series TO 5. One (1) warrant series TO 4 entitles the holder to subscribe for one (1) new share in the Company during the period 7 - 21 June 2024 at an exercise price of SEK 0.02 per share and one (1) warrant series TO 5 entitles the holder to subscribe for one (1) new share in the Company during the period 21 November - 5 December 2024 at an exercise price of SEK 0.0225 per share.

In the event of full exercise of all warrants of series TO 4, the Company will receive approximately MSEK 21.0 before issue costs. In order for the warrants not to expire and lose their value, they must be actively sold by 18 June 2024 at the latest, or be exercised no later than 21 June 2024.

Note that warrants that have not been actively sold by 18 June 2024 at the latest, or been exercised no later than 21 June 2024, will expire and lose their value.

Exercise of warrants series TO 4
Trustee-registered warrants

If the warrant holder holds warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercise of the warrants.

Directly registered warrants (securities account)

Directly registered warrant holders can order an application form via info@eminova.seor by phone on +46 8-684 211 00. Payment is made in accordance with the instructions in the application form. Both the application form and payment must be submitted to Eminova Fondkommission AB by 15.00 CEST on 24 June 2024 at the latest.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34